Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GCK | P35557 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304773 | 0.93 | GCK (0.33) | GCK | |
| SCHEMBL1078871 | 0.90 | GCK (0.33) | GCK | |
| SCHEMBL1060470 | 0.89 | HDAC8 (0.39) | HDAC8RAB9AGCKMAPTNPC1 | |
| SCHEMBL4289059 | 0.88 | HDAC8 (0.40) | HDAC8RAB9AGCKMAPTNPC1 | |
| SCHEMBL1065503 | 0.87 | GCK (0.42) | GCK | |
| SCHEMBL1063248 | 0.87 | GCK (0.42) | GCK | |
| SCHEMBL1061850 | 0.86 | GCK (0.42) | GCK | |
| SCHEMBL1080460 | 0.86 | GCK (0.49) | GCK | |
| SCHEMBL4290688 | 0.81 | STIM1 (0.35) | RAB9AGCKMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4295913 | 0.81 | STIM1 (0.35) | RAB9AGCKMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | HDAC8 1783/4885RAB9A 3487/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.